Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 8/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 3/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11587612 | 0.91 | CA2 (0.44) | CA2ALDH1A1MAPK1CYP3A4TSHR | |
| SCHEMBL227552 | 0.86 | CA2 (0.41) | CA2ALDH1A1MAPK1CYP3A4TSHR | |
| SCHEMBL20610374 | 0.82 | CA2 (0.47) | CA2ALDH1A1MAPK1CYP3A4TSHR | |
| SCHEMBL1116222 | 0.82 | CA2 (0.48) | CA2ALDH1A1MAPK1CYP3A4TSHR | |
| SCHEMBL5718430 | 0.82 | CA2 (0.47) | CA2ALDH1A1MAPK1CYP3A4TSHR | |
| SCHEMBL27868183 | 0.82 | CA2 (0.48) | CA2ALDH1A1MAPK1CYP3A4TSHR | |
| SCHEMBL28846366 | 0.82 | CA2 (0.39) | CA2ALDH1A1MAPK1CYP3A4TSHR | |
| SCHEMBL27614111 | 0.82 | CYP3A4 (0.42) | CA2ALDH1A1MAPK1CYP3A4TSHR | |
| SCHEMBL7201092 | 0.81 | CA2 (0.37) | CA2ALDH1A1MAPK1CYP3A4TSHR | |
| SCHEMBL11355584 | 0.81 | CA2 (0.50) | CA2ALDH1A1MAPK1CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3438083-B1 | ALKOXY MAGNESIUM, METHOD FOR PRODUCING ALKOXY MAGNESIUM, SOLID CATALYST COMPONENT FOR OLEFIN POLYMERIZATION USE, CATALYST FOR OLEFIN POLYMERIZATION USE, AND METHOD FOR PRODUCING OLEFIN POLYMER | TOHO TITANIUM CO LTD (JP) | 2023-08-16 | — | — | EP | claimed |
| EP-3662044-B1 | DETERGENT ADDITIVE | DOW GLOBAL TECHNOLOGIES LLC (US) | 2022-08-03 | — | — | EP | claimed |
| EP-3662049-B1 | ENCAPSULATION METHOD | DOW GLOBAL TECHNOLOGIES LLC (US) | 2021-05-05 | — | — | EP | claimed |
| US-20260117617-A1 | EXPANDABLE POLYMER GROUT FOR SAND CONTROL IN A WELL | CHEVRON USA INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-12612839-B1 | Expandable polymer grout for sand control in a well | CHEVRON U.S.A. INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20260063011-A1 | EXPANDABLE POLYMER GROUT FOR WELLBORE APPLICATIONS | CHEVRON USA INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-12428931-B2 | Cement top jobs in wellbore annuli using expandable compositions | CHEVRON U.S.A. INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20250250878-A1 | EXPANDABLE POLYMER GROUT FOR SEALING SUBTERRANEAN FORMATIONS | CHEVRON U.S.A. INC. | 2025-08-07 | — | — | US | disclosed |
| US-12378842-B1 | Expandable polymer grout for sealing subterranean formations | CHEVRON U.S.A. INC. (US) | 2025-08-05 | — | — | US | disclosed |
| US-12134950-B2 | Deployment methods for expandable polymer grout for plug and abandonment applications | CHEVRON U.S.A. INC. (US) | 2024-11-05 | — | — | US | disclosed |
| US-12097532-B2 | Method for forming multilayer coating film | KANSAI PAINT CO., LTD. (JP) | 2024-09-24 | — | — | US | disclosed |
| WO-2009112403-A2 | DIMERIC BENZYLIDENE MALONATES | BASF SE (DE) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009091909-A2 | DEGRADABLE NON-AQUEOUS GEL SYSTEMS | M-I L.L.C. (US) | 2009-07-23 | — | — | WO | disclosed |
| WO-2008147641-A1 | ISOCYANATE-EPOXY FORMULATIONS FOR IMPROVED CURE CONTROL | DOW GLOBAL TECHNOLOGIES INC. (US) | 2008-12-04 | — | — | WO | disclosed |
| WO-2008134359-A1 | USE OF ELASTOMERS TO PRODUCE GELS FOR TREATING A WELLBORE | M-I LLC (US) | 2008-11-06 | — | — | WO | disclosed |
| US-7217820-B2 | Cosmetic or pharmaceutical preparations which comprise enaminotriazines as light protection agents, and novel enaminotriazines | BASF AKTIENGESELLSCHAFT (DE) | 2007-05-15 | — | — | US | disclosed |
| US-6891012-B2 | Powder coatings produced with crosslinkers capable of curing at low temperatures and coated articles produced therefrom | BAYER MATERIALSCIENCE LLC (US) | 2005-05-10 | — | — | US | disclosed |
| US-20040236021-A1 | Powder coatings produced with crosslinkers capable of curing at low temperatures and coated articles produced therefrom | BAYER MATERIALSCIENCE LLC | 2004-11-25 | — | — | US | disclosed |
| EP-1479705-A1 | Powder coatings produced with crosslinkers capable of curing at low temperatures and coated articles produced therefrom | Bayer MaterialScience LLC (US) | 2004-11-24 | — | — | EP | disclosed |
| US-5415854-A | Sunscreen agents | L'OREAL (FR) | 1995-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260063011-A1 | EXPANDABLE POLYMER GROUT FOR WELLBORE APPLICATIONS | HPSE, HIRIP3, WEE2 | CA2 855/4885ALDH1A1 4718/4885MAPK1 2989/4885 |
| US-12612839-B1 | Expandable polymer grout for sand control in a well | GET3, USE1, WEE2 | CA2 1447/4885ALDH1A1 4408/4885MAPK1 3759/4885 |
| US-20260117617-A1 | EXPANDABLE POLYMER GROUT FOR SAND CONTROL IN A WELL | GET3, WEE1, WEE2 | CA2 1677/4885ALDH1A1 4547/4885MAPK1 4000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.